- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Giacomini to lead $15.1 million in research funding to improve the use of drugs in individuals
By UCSF School of Pharmacy Editorial Staff / Tue Sep 7, 2010
Kathy Giacomini, PhD, co-chair of the UCSF Department of Bioengineering and Therapeutic Sciences and an expert in the field of pharmacogenomics, is leading two research projects funded by two grants totaling $15.1 million over the next five years to expand research into how genes affect an individual's response to medication and to strengthen a global network of researchers involved in these efforts. The grants are the largest portion of a $161.3 million total effort by the National Institutes of Health to expand a national collaboration of scientists known as the Pharmacogenomics Research Network with the goal of paving the way for personalized medicine.
More
Tags
Keywords:
Category:
Sites:
School of Pharmacy, Department of Bioengineering and Therapeutic Sciences, PharmD Degree Program, BMI, QBC, PSPG, Bioinformatics
Related profiles
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.
Related news
- School of Pharmacy leads in NIH funding for the 44th straight year
- Giacomini receives Dawson Award
- Giacomini to receive Therapeutic Frontiers Lecture Award
- Reflection: 30 years of top NIH funding for UCSF School of Pharmacy
- Giacomini to lead largest study of genetic, ethnic differences in effectiveness of leading diabetes drug
